Medical device firm NanoVibronix has launched the first ever hands-free ultrasound device for pain relief in the US.
The launch follows the receipt of 510k clearance from US Food and Drug Administration (FDA) to market PainShield MD, which was created in Nesher, Israel.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PainShield MD is the first hands-free, patch-based device designed to allow for an entirely new dimension in ultrasound treatment of pain and soft tissue healing, and is claimed to have reduced pain and help nerve recovery in several studies.
Integrated with advanced technology, the device consists of a disposable patch connected to a portable reusable driver that propagates therapeutic ultrasound waves to the desired area of the body.
NanoVibronix president William Stern said: "PainShield MD, which implements our unique low frequency, low intensity ultrasound platform, is the first product from our pipeline to be cleared for marketing in the US and represents a major milestone for NanoVibronix.
"We have created a platform that changes the way pain, the most common medical complaint, is managed.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"Our simple-to-use, portable device can treat pain locally including trigeminal neuralgia, chronic pelvic pain, tendonitis, musculoskeletal disorders and post-operative pain."
NanoVibronix sales director Lindsey Harrison said: "Patients now have an option for pain relief in the convenience of their own home, even while performing their normal activities.
"The hands-free feature allows patients access to technology that was never before available outside of a clinical setting."
PainShield MD may help avoid trigeminal neuralgia surgery, which is severe spastic, lancinating facial pain due to a disorder of the fifth cranial nerve.
In addition, the device is designed to facilitate long treatment sessions of up to six hours daily, which are more effective than conventional products.
